Dianthus Q2 net loss $31.6M ($0.88/sh); cash $309.1M; gMG Ph2 data due Sept

Dianthus Therapeutics, Inc. /DE/

2025-Q2 EPS reported -$1.71 revenue$1,356,000

Cash, cash equivalents and investments $309.1M as of June 30, 2025; runway into 2H 2027.
Net loss $31.6M ($0.88 basic/diluted EPS) vs $17.6M ($0.51) in Q2 2024.
R&D expenses $26.3M (incl. $2.5M stock-based) vs $18.1M; increase driven by Phase 2/3 costs.
Top-line Phase 2 MaGic trial results for claseprubart in gMG anticipated September 2025.
Phase 3 CAPTIVATE CIDP trial on track; interim responder analysis expected 2H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.